Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of genetically-supported new drug targets for osteomyelitis based on druggable genomes.

Human genomics - 7 Oct 2025

Yao Ruotong, Lu Yangguang, Lu Di, Ren Haiyong, Wang Xiang, Lin Bingyuan, Chen Siyao, Zhu Yusheng, Chen Feng, Wang Yukai, Gao Yi, Shen Jiawen, Guo Qiaofeng, Huang Kai

Abstract excerpt

BACKGROUND: Limited drug treatment data are available for osteomyelitis (OM), an inflammatory bone condition secondary to infection. Given its genetic characteristics, it is necessary to integrate genetics into drug development for osteomyelitis. This study applied pharmacogenomics to identify new drug targets for osteomyelitis using Mendelian randomization (MR). METHODS: Following the Strengthening the Reporting...

Read the complete abstract on PubMed

Topics

Humans
Genetic Predisposition to Disease
Genome-Wide Association Study
Mendelian Randomization Analysis
Osteomyelitis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Pharmacogenetics

Polymorphism, Single Nucleotide

Quantitative Trait Loci

Observational Studies as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 41057938
DOI: 10.1186/s40246-025-00826-6
PMCID: PMC12505852

Genes

LAMC1
LTA4H
NEK6
QDPR
ABAT
CBR3
FPR1
LTB4R
MAPK3
NTSR1
TGM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 26 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of genetically-supported new drug targets for osteomyelitis based on druggable genomes.PMID 41057938Read ↗

Identification of therapeutic targets for rheumatic heart valve disease based on systematic druggable genome wide Mendelian randomization.Semantic proximity Read ↗

Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization studySemantic proximity Read ↗

Genetically Supported Drug Targets and Dental Traits: A Mendelian Randomization Study.Semantic proximity Read ↗

Osteomyelitis and immune cell phenotypes: a study based on a Mendelian randomisation approachSemantic proximity Read ↗

Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study.Semantic proximity Read ↗

Mendelian randomization analysis to identify potential drug targets for osteoarthritisSemantic proximity Read ↗

Integrative Analysis of Genetic, Proteomic, and Transcriptomic Data Reveals Novel Therapeutic Targets for Rheumatoid ArthritisSemantic proximity Read ↗

Integrative mendelian randomization approaches for therapeutic target prioritisation in immune-mediated diseases.Semantic proximity Read ↗

Circulating inflammatory proteins and osteomyelitis: A bidirectional Mendelian randomization and colocalization analysis.Semantic proximity Read ↗

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.Semantic proximity Read ↗

Integrative Mendelian Randomization approaches for therapeutic target prioritisation in immune-mediated diseasesSemantic proximity Read ↗

Optimizing Mendelian Randomization for Drug Prediction: Exploring Validity and Research StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.